A study released Friday found that kid-size doses of Pfizer’s COVID-19 vaccine are nearly 91 percent effective at preventing symptomatic infections in 5- to 11-year-olds.
Aiden Arthurs receives the Pfizer-BioNTech Covid-19 Vaccine from Pharmacist Andrew Mac at the Jewish Federation/JARC's offices in Bloomfield Hills, Mich., on May 13, 2021.Kid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91 percent effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group.
Details of Pfizer's study posted online Friday. Advisers to the Food and Drug Administration will publicly debate the evidence next week.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Pfizer says COVID-19 vaccine more than 90% effective in kidsPfizer says kid-size doses of its COVID-19 vaccine are safe and nearly 91% effective at preventing symptomatic infections in elementary school children
Les mer »
Pfizer says COVID-19 vaccine more than 90% effective in kidsKid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group.
Les mer »
Pfizer says COVID-19 vaccine more than 90% effective in kidsKid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group. The shots could begin in early November — with the first children in line fully protected by Christmas — if regulators give the go-ahead. Details of Pfizer's study were posted online.
Les mer »
Pfizer, BioNTech report high efficacy of COVID-19 booster shot in studyPfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.
Les mer »
Pfizer/BioNTech COVID-19 vaccine shows 90.7% efficacy in trial in childrenThe Pfizer /BioNTech COVID-19 vaccine showed 90.7% efficacy against the coronavirus in a clinical trial of children 5 to 11 years old, the U.S. drugmaker said on Friday.
Les mer »
Pfizer Says Its Booster Shot Shows 95.6% Efficacy Against Covid-19I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Les mer »